Certara Shanghai relocates to a new location and sets sail for a new era

Certara Shanghai relocated the office and held a grand opening ceremony at Hong Kong Plaza in Huangpu District, Shanghai on September 9, 2022. The goal of this move was to provide greater support to local customers  and facilitate meeting market needs. Customers and key opinion leaders in China were invited to the ceremony where they … Continued

Certara to Host Second Annual Symposium Dedicated to Advancing Pediatric Drug Development

PRINCETON, N.J., September 25, 2022 – Certara, a global leader in biosimulation, today announced it will host the second annual New Horizons in Pediatric Drug Development Symposium from October 27-28, 2022. The two-day virtual symposium brings together global thought leaders from academia, industry, patient advocacy organizations and health authorities to discuss the latest innovations in … Continued

Certara Announces Second Year of Fellowship Program in Africa for Applied Pharmacometrics Training

PRINCETON, N.J.— September 25, 2022 — Certara, Inc, a global leader in biosimulation, today announced that it is expanding its Applied Pharmacometrics Training (APT) fellowship program for doctoral-level scientists from Africa, in partnership with Pharmacometrics Africa, CP+ Associates, and other industry and academic partners.  After its successful first year with sixteen fellows, the program has … Continued

Certara Hosts Seminar on Drug Discovery Challenges in Japan and How Modeling and Simulation Can Solve Them

“Quantitative decision-making with data rather than empirical thinking” – Certara’s Modeling & Simulation technology contributes to accelerate new drug development Certara G.K. held an online press seminar on Wednesday, August 31, 2022, in Tokyo, on the optimization of the drug development process and the role of a drug discovery consulting company. In Japan, local demand … Continued

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of Pharmacy and Bio-AI Convergence Research Center of Chungnam National University, listed as a guest presenter at key Pharmacometrics conferences across the Asia-Pacific region, as well as at local Korean events. In 2020, he also presented to a large audience at … Continued

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and population PK analysis. Recently, we have seen how Certara software helps customers accelerate collaboration across their divisions and groups for better clinical results. Today, we interviewed Sun Hua, Associate Chief Pharmacist at Yijishan Hospital, Drug Evaluation Center, Wannan Medical College, … Continued

Certara Completes Acquisition of Pinnacle 21

Complementary technologies accelerate and help assure success in the drug development process Princeton, N.J., October 4, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.  … Continued

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

Cloud-based and validated regulatory software automates and advances quality of patient narratives Princeton, N.J., September 30, 2021 – Certara, a global leader in biosimulation, today announced the launch of Synchrogenix™ Writer, a new regulatory SaaS product that expedites the authoring and review of patient narratives. Patient narratives describe adverse events or adverse drug reactions and … Continued

Certara Strengthens Model-Informed Drug Development Team with Four Executive Hires

New executives bring cross-disciplinary expertise and diversity to the company’s premier global Integrated Drug Development team PRINCETON, N.J.—May 17, 2021. Certara, Inc, (Nasdaq: CERT), the global leader in biosimulation, announced the appointments of four executives to its growing model-informed drug development team: Dr. Matt Zierhut as Vice President, Model-Based Meta-Analysis, Dr. James Dunyak as Senior … Continued

Demonstrating Virtual Bioequivalence (VBE) using the Simcyp Simulator™

Demonstrating bioequivalence (BE) remains the key regulatory hurdle for genericdrug approval. As a result, some branded drugs remain on the market well pastthe originator’s patent expiration, without cost-effective generic alternatives thatcould benefit patients. Model-informed drug development (MIDD), specificallyphysiologically-based pharmacokinetics (PBPK) leveraging in vitro data, is a proven,cost-effective option to consider in lieu of running an … Continued

1 of 13
Powered by Translations.com GlobalLink OneLink Software